• Prescribing Information
• |
• Important Safety Information
• |
• Patient Product Information

 

 

If you have a detectable viral load and have experienced treatment failure with previous drug regimens, FUZEON may be an option for you.

It may be time to talk to your healthcare provider about FUZEON if you have only 1 fully active agent in your current regimen. According to the Department of Health and Human Services Guidelines, adding at least 2, and preferably 3, fully active agents to an optimized-background antiretroviral regimen can provide significant antiretroviral activity.¹

1. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. November 3, 2008; 1-139. Available at http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. Accessed November 5, 2008.

• 
• 

© 2010 Genentech USA, Inc. & Trimeris, Inc.

For more information about FUZEON contact your physician or other healthcare professional. FUZEON is a registered trademark of Genentech USA, Inc. and Trimeris, Inc.

THIS SITE IS INTENDED FOR U.S. AUDIENCES ONLY.

Copyright © 2010 Genentech USA, Inc. and Trimeris, Inc. All rights reserved. Use and access of this site are subject to the terms and conditions as set out in our Legal Statement and Privacy Statement.